AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38652523 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical signs of right heart failure (RHF)
Number of subjects: 0
Study 38652523 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction (RVD)
Number of subjects: 0
Study 38652523 — intervention group
Group type: EXPERIMENTAL
Intervention: Different right ventricular maladaptation patterns (isolated right ventricular dilatation, isolated pulmonary hypertension, combined pattern)
Number of subjects: 0
Study 38652564 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy initiation (ARTi)
Number of subjects: 23
Study 38652564 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute antiretroviral therapy initiation (ARTi)
Number of subjects: 23
Study 38652568 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided TN PRF at 42°C for 240 s
Number of subjects: 49
Study 38652568 — intervention group
Group type: COMPARATOR
Intervention: FL-guided intralesional RFT at 80°C for 90 s
Number of subjects: 49
Study 38652568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 49
Study 38652585 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety, pain, and theta power
Number of subjects: 63
Study 38652585 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, poorer sleep quality, lower motor threshold, and higher relative theta power
Number of subjects: 63
Study 38652585 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation-indexed motor threshold and psychosocial variables
Number of subjects: 63
Study 38652585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity and higher theta oscillations
Number of subjects: 63
Study 38652666 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38652666 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable diagnostic testing followed by laboratory-quality testing
Number of subjects: 0
Study 38652666 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire screening
Number of subjects: 0
Study 38652666 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable Apnea Prediction Index (MAPI) followed by portable diagnostic testing and laboratory-quality testing
Number of subjects: 0
Study 38652666 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-quality testing for all
Number of subjects: 0
Study 38652666 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for all patients
Number of subjects: 0
Study 38652691 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention including enhanced communication skills, goal setting, safer sex behaviors, drug refusal skills, and life satisfaction.
Number of subjects: 602
Study 38652691 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological capital as a construct.
Number of subjects: 602
Study 38652801 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 65
Study 38652801 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 65
Study 38652801 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 65
Study 38652812 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention for high-risk smoldering multiple myeloma
Number of subjects: 54
Study 38652812 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiling
Number of subjects: 54
Study 38652812 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk scores
Number of subjects: 54
Study 38652877 — intervention group
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan (Dato-DXd)
Number of subjects: 85
Study 38652891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) every 4 weeks
Number of subjects: 18
Study 38652891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) withdrawal
Number of subjects: 18
Study 38652891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) successfully stopped
Number of subjects: 18
Study 38652978 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-BF) training sessions in addition to pharmacological standard therapy
Number of subjects: 64
Study 38652978 — intervention group
Group type: COMPARATOR
Intervention: Standard therapies for 10 weeks (Control group)
Number of subjects: 64
Study 38652999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 100 mg/day
Number of subjects: 394
Study 38652999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 200 mg/day
Number of subjects: 394
Study 38652999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg/day
Number of subjects: 394
Study 38652999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 394
Study 38652999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 38653060 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic lesions from primary mixed IBC-NST/ILC
Number of subjects: 2
Study 38653177 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation augmented with Savoring (BA + S)
Number of subjects: 60
Study 38653177 — intervention group
Group type: COMPARATOR
Intervention: Emotional Awareness (EA)
Number of subjects: 60
Study 38653350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 203
Study 38653350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/esketamine post-discharge
Number of subjects: 203
Study 38653350 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ketamine studies)
Number of subjects: 203
Study 38653496 — intervention group
Group type: EXPERIMENTAL
Intervention: Colectomy with the novel miniaturized robotic-assisted surgery device
Number of subjects: 30
Study 38653508 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (3.75, 7.5 or 15 mg/m2)
Number of subjects: 45
Study 38653508 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 45
Study 38653508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 38653513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindmore Remote digitalized neuropsychological test battery
Number of subjects: 300
Study 38653513 — intervention group
Group type: COMPARATOR
Intervention: Traditional neuropsychological assessment face-to-face
Number of subjects: 300
Study 38653618 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg once daily for three months
Number of subjects: 50
Study 38653618 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets once daily for three months
Number of subjects: 50
Study 38653808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia fiber (AF) 10 g
Number of subjects: 180
Study 38653808 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium Lactis (BLa80) 4 g
Number of subjects: 180
Study 38653808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 38653864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 35
Study 38653903 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi (Suliqua) administered once daily
Number of subjects: 0
Study 38653903 — intervention group
Group type: COMPARATOR
Intervention: MDI regimen continuation
Number of subjects: 0
Study 38653903 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 38653979 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2/8-hCYP4V2 gene therapy (single unilateral subretinal injection of 7.5 × 10^11 vg)
Number of subjects: 12
Study 38653983 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered at escalating doses of 0.5 × 10^6 cells/kg.
Number of subjects: 18
Study 38654004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicocranial flexion exercise (CCFE) and neck flexor endurance training plus normal cardiopulmonary rehabilitation
Number of subjects: 13
Study 38654004 — intervention group
Group type: COMPARATOR
Intervention: General neck stretching exercises plus cardiopulmonary rehabilitation
Number of subjects: 13
Study 38654151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrhythmias (≥2 kinds of arrhythmias)
Number of subjects: 23825
Study 38654151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachyarrhythmias
Number of subjects: 23825
Study 38654151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradyarrhythmias
Number of subjects: 23825
Study 38654151 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial tachyarrhythmias
Number of subjects: 23825
Study 38654151 — intervention group
Group type: EXPERIMENTAL
Intervention: Any arrhythmias
Number of subjects: 23825
Study 38654198 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation triage and referral system
Number of subjects: 100
Study 38654198 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of semi-structured interviews
Number of subjects: 100
Study 38654329 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) provided by general practitioners or general practice staff after a 2-day PST course
Number of subjects: 188
Study 38654329 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 188
Study 38654329 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 188
Study 38654367 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Wheelchair driving simulator (VR)
Number of subjects: 31
Study 38654367 — intervention group
Group type: COMPARATOR
Intervention: Real circuit driving (R)
Number of subjects: 31
Study 38654416 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly effective disease-modifying therapy
Number of subjects: 8557
Study 38654416 — intervention group
Group type: COMPARATOR
Intervention: Moderately effective disease-modifying therapy
Number of subjects: 8557
Study 38654416 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease-modifying therapy exposure
Number of subjects: 8557
Study 38654416 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted prevalence of MS
Number of subjects: 8557
Study 38654416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence by demographic subgroup
Number of subjects: 8557
Study 38654422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg once daily for 24 weeks
Number of subjects: 703
Study 38654422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg once daily for 24 weeks
Number of subjects: 703
Study 38654422 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg once daily for 24 weeks
Number of subjects: 703
Study 38654422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg at 12 weeks
Number of subjects: 703
Study 38654422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg at 12 weeks
Number of subjects: 703
Study 38654422 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole at 12 weeks
Number of subjects: 703
Study 38654422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 703
Study 38654422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 703
Study 38654422 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 703
Study 38654565 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 0
Study 38654565 — intervention group
Group type: COMPARATOR
Intervention: Prolonged DAPT (12-month or longer)
Number of subjects: 0
Study 38654917 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised and home-based exercise training
Number of subjects: 50
Study 38655380 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mental health interventions (DMHIs) for adolescent depression prevention
Number of subjects: 0
Study 38655380 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and recruitment activities for the P2P trial
Number of subjects: 0
Study 38655672 — intervention group
Group type: EXPERIMENTAL
Intervention: Surefil One self-adhesive bulk-fill composite
Number of subjects: 64
Study 38655672 — intervention group
Group type: COMPARATOR
Intervention: Filtek One bulk-fill composite with Scotchbond Universal adhesive in self-etch mode
Number of subjects: 64
Study 38655676 — intervention group
Group type: EXPERIMENTAL
Intervention: NTHi vaccine antigens
Number of subjects: 0
Study 38655693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using a variable-loop circular catheter with 3D mapping integration
Number of subjects: 186
Study 38655793 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured weight management programs
Number of subjects: 0
Study 38655793 — intervention group
Group type: COMPARATOR
Intervention: Obesity pharmacotherapeutics
Number of subjects: 0
Study 38655842 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/EVG inserts (20 mg/16 mg) administered rectally
Number of subjects: 0
Study 38655852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Yoga and Yogic Breathing
Number of subjects: 20
Study 38655990 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Actiregularis strain (5×106 cfu/ml) added to maternal diet once daily for 15 days
Number of subjects: 0
Study 38655998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium priming (10% of the rocuronium dose administered 3 min before induction)
Number of subjects: 52
Study 38655998 — intervention group
Group type: COMPARATOR
Intervention: Standard rapid sequence intubation
Number of subjects: 52
Study 38655998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium priming
Number of subjects: 52
Study 38656145 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted patellofemoral arthroplasty (PFA)
Number of subjects: 44
Study 38656217 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline postexposure prophylaxis (doxy-PEP)
Number of subjects: 44
Study 38656229 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone antagonist degarelix
Number of subjects: 29
Study 38656252 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38656355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia melanocarpa extract (AME) 180 mg anthocyanins/day
Number of subjects: 35
Study 38656355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 38656372 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity Surgery (OS)
Number of subjects: 24
Study 38656372 — intervention group
Group type: COMPARATOR
Intervention: Low-Calorie Diet (LCD)
Number of subjects: 24
Study 38656413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-ring, plastic wound protector
Number of subjects: 457
Study 38656413 — intervention group
Group type: COMPARATOR
Intervention: Surgical gauze (control)
Number of subjects: 457
Study 38656557 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpibectir (0.5 to 40 mg) administered as single daily doses in fasted and fed conditions.
Number of subjects: 80
Study 38656557 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpibectir (5 to 30 mg) administered once daily for 7 days in multiple ascending doses.
Number of subjects: 80
Study 38656557 — intervention group
Group type: COMPARATOR
Intervention: Alpibectir under fed conditions (10 mg).
Number of subjects: 80
Study 38656557 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpibectir (various doses) in multiple ascending doses.
Number of subjects: 80
Study 38656566 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 190
Study 38656566 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 190
Study 38656566 — intervention group
Group type: COMPARATOR
Intervention: CDSS
Number of subjects: 190
Study 38656579 — intervention group
Group type: EXPERIMENTAL
Intervention: MP (migraine as patient)
Number of subjects: 366
Study 38656579 — intervention group
Group type: EXPERIMENTAL
Intervention: MH (migraine as healthy)
Number of subjects: 366
Study 38656579 — intervention group
Group type: COMPARATOR
Intervention: HC (headache-free controls)
Number of subjects: 366
Study 38656736 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894 (100 mg)
Number of subjects: 24
Study 38656736 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894 (200 mg)
Number of subjects: 24
Study 38656736 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894 (50 mg and 100 mg)
Number of subjects: 24
Study 38656736 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1358894
Number of subjects: 24
Study 38656736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 38656781 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) intervention
Number of subjects: 152
Study 38656931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study 38656931 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study 38656931 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study 38656951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafeteria intervention encouraging healthy foods and discouraging unhealthy foods for six months
Number of subjects: 277
Study 38657001 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 642
Study 38657001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 38657084 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo, Ad26.ZEBOV administered 14 days apart (n = 79)
Number of subjects: 499
Study 38657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo administered 28 days apart (n = 322)
Number of subjects: 499
Study 38657084 — intervention group
Group type: COMPARATOR
Intervention: Saline/placebo (n = 98)
Number of subjects: 499
Study 38657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine regimens (14-day and 28-day)
Number of subjects: 499
Study 38657201 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab (1.5 mg/kg)
Number of subjects: 165
Study 38657227 — intervention group
Group type: EXPERIMENTAL
Intervention: MASP+ app
Number of subjects: 72
Study 38657227 — intervention group
Group type: COMPARATOR
Intervention: National Cancer Institute's QuitGuide app
Number of subjects: 72
Study 38657244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential CD7 CAR T-cell therapy
Number of subjects: 10
Study 38657244 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical HSCT without pharmacologic myeloablation or GVHD prophylaxis
Number of subjects: 10
Study 38657244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 10
Study 38657244 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 10
Study 38657244 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after CAR T-cell therapy
Number of subjects: 10
Study 38657244 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission status
Number of subjects: 10
Study 38657265 — intervention group
Group type: EXPERIMENTAL
Intervention: Exagamglogene autotemcel (exa-cel)
Number of subjects: 52
Study 38657345 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 93
Study 38657345 — intervention group
Group type: COMPARATOR
Intervention: Control (Chemotherapy)
Number of subjects: 93
Study 38657366 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 0
Study 38657398 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 82
Study 38657398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 82
Study 38657530 — intervention group
Group type: EXPERIMENTAL
Intervention: ChatGPT-4 predictions
Number of subjects: 2851
Study 38657730 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Management (MM)
Number of subjects: 0
Study 38657730 — intervention group
Group type: EXPERIMENTAL
Intervention: MM plus Connections (CHESS health) digital smartphone application (MMD)
Number of subjects: 0
Study 38657730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Buprenorphine with taper
Number of subjects: 0
Study 38657730 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release Buprenorphine with taper
Number of subjects: 0
Study 38657731 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine care for MS
Number of subjects: 120
Study 38657731 — intervention group
Group type: COMPARATOR
Intervention: In-clinic care for MS
Number of subjects: 120
Study 38657732 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital, coach-assisted intervention targeting hope
Number of subjects: 150
Study 38657732 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 150
Study 38657773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (3-12 mg/d)
Number of subjects: 930
Study 38657773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 38657999 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment with moisturising cream, performed at 630 nm two times per week in palmoplantar areas (4 J/cm²)
Number of subjects: 40
Study 38657999 — intervention group
Group type: COMPARATOR
Intervention: Sham PBM treatment with moisturising cream
Number of subjects: 40
Study 38658010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 1000
Study 38658010 — intervention group
Group type: COMPARATOR
Intervention: vNOTES (vaginal natural orifice transluminal endoscopic surgery)
Number of subjects: 1000
Study 38658010 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hysterectomy (LH)
Number of subjects: 1000
Study 38658012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track total hip arthroplasty (THA)
Number of subjects: 1400
Study 38658012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track total knee arthroplasty (TKA)
Number of subjects: 1400
Study 38658012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track unicompartmental knee arthroplasty (UKA)
Number of subjects: 1400
Study 38658012 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative diabetes treatment
Number of subjects: 1400
Study 38658017 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological and molecular features assessment
Number of subjects: 223